AU2001274934A1 - Human circulating dendritic cell compositions and methods - Google Patents
Human circulating dendritic cell compositions and methodsInfo
- Publication number
- AU2001274934A1 AU2001274934A1 AU2001274934A AU7493401A AU2001274934A1 AU 2001274934 A1 AU2001274934 A1 AU 2001274934A1 AU 2001274934 A AU2001274934 A AU 2001274934A AU 7493401 A AU7493401 A AU 7493401A AU 2001274934 A1 AU2001274934 A1 AU 2001274934A1
- Authority
- AU
- Australia
- Prior art keywords
- binding agent
- cells
- cirdc
- selective binding
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 126
- 239000000203 mixture Substances 0.000 title claims description 55
- 210000004443 dendritic cell Anatomy 0.000 title claims description 43
- 241000282414 Homo sapiens Species 0.000 title claims description 23
- 239000011230 binding agent Substances 0.000 claims description 123
- 210000004027 cell Anatomy 0.000 claims description 121
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 85
- 210000000265 leukocyte Anatomy 0.000 claims description 70
- 210000001616 monocyte Anatomy 0.000 claims description 55
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 50
- 230000001225 therapeutic effect Effects 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 210000003714 granulocyte Anatomy 0.000 claims description 35
- 230000000779 depleting effect Effects 0.000 claims description 29
- 230000001483 mobilizing effect Effects 0.000 claims description 27
- 239000011324 bead Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 15
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 13
- 230000005298 paramagnetic effect Effects 0.000 claims description 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 11
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 11
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 11
- 210000005087 mononuclear cell Anatomy 0.000 claims description 11
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 5
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims description 5
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 5
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 5
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 5
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 5
- -1 IL-14 Proteins 0.000 claims description 4
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 4
- 108010059631 myelopoietin Proteins 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 3
- 102100032768 Complement receptor type 2 Human genes 0.000 claims description 3
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims description 3
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 235000021120 animal protein Nutrition 0.000 claims description 3
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 2
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 2
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 102000000646 Interleukin-3 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 108010002335 Interleukin-9 Proteins 0.000 claims description 2
- 102100039564 Leukosialin Human genes 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 claims description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 108010017136 daniplestim Proteins 0.000 claims description 2
- 229950001607 daniplestim Drugs 0.000 claims description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 2
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 239000000427 antigen Substances 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 9
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 9
- 238000002617 apheresis Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000005291 magnetic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 238000010187 selection method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000008105 immune reaction Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 210000005208 blood dendritic cell Anatomy 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000011488 interferon-alpha production Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
HUMAN CIRCULATING DENDRITIC CELL COMPOSITIONS AND METHODS
BACKGROUND OF THE INVENTION
The present invention relates generally to hematopoietic cells and, more specifically, to methods for producing human circulating dendritic cells for therapeutic use.
Dendritic cells (DCs) are white blood cells that are specialized to present both self and foreign molecules (antigens) to the immune system. Uptake, processing and presentation of antigens by dendritic cells can activate T lymphocytes to recognize and mount an effective immunological attack against cells expressing the antigen.
Although no single surface marker is uniquely associated with dendritic cells, DCs can be distinguished from other hematopoietic cells by their lack of expression of surface marker profiles associated with B cells, T cells, monocytes, NK cells, in combination with high expression of the major histocompatibility antigens. Dendritic cells can also be distinguished from other hematopoietic cells by their ability to stimulate a mixed lymphocyte reaction in vi tro with an efficacy of about 100 times that of other hematopoietic cell types.
The ability of dendritic cells to modulate the immune response allows DCs to be used therapeutically in the treatment of infectious diseases and cancer. In one current form of immunotherapy, DCs are pulsed ex vivo with an antigen associated with the infectious agent or tumor cell, to create antigen-pulsed dendritic cells.
The antigen-pulsed DCs can be reintroduced into the body to stimulate T lymphocytes in vivo to recognize and attack the pathogenic cells. Antigen-pulsed dendritic cells can also be used to prime large numbers of T lymphocytes ex vivo in a co-culture, and the antigen-specific activated T cells can be introduced into the patient to combat the disease.
Human dendritic cells for use in immunotherapeutic procedures have been produced by culturing peripheral blood mononuclear cells (PBMCs) ex vivo in the presence of hematopoietic growth factors or other additives in order to promote the proliferation and differentiation of dendritic precursor cells into dendritic cells (see, for example, WO 98/06823 and WO 98/06826) . Such procedures, while producing clinically relevant numbers of dendritic cells, are laborious and time-consuming, as ex vivo maturation of the dendritic cells requires culturing the cells for many days. It is also unclear whether the DCs obtained by culturing procedures have the identical functional, morphological and phenotypic characteristics as dendritic cells matured in vivo.
Dendritic cells are present in small numbers in a variety of tissues, including lymphoid organs, skin, and circulating blood. Although blood is the most convenient source of dendritic cells, DCs make up only about 1% of the leukocytes in the blood, which has made it difficult to obtain sufficient numbers of high quality blood dendritic cells (cirDC) for therapeutic purposes.
Several methods of enriching for cirDC for research applications have been described. For example, Robinson et al . , Eur. J. Immunol . 29:2769-2778 (1999)),
describes subjecting buffy coats to serial density gradient centrifugation through stepwise FICOLL or PERCOLL gradients, followed by immunomagnetic depletion of B cells, T cells, monocyte and NK cell populations using CD3 , CD14, CD20 and CD16 antibodies. Kohrgruber et al., J. Immunol. 163:3250-3259 (1999), describes FICOLL separation of an apheresis product followed by counterflow elutriation to remove debris and small lymphocytes. The pooled elutriation fractions were immunomagnetically depleted of T, B, NK, hematopoietic stem cells and monocytes using a cocktail of anti-CD3, CDllb, CD16, CD19, CD34 and CD56 antibodies.
Miltenyi Biotec (Gladbach, Germany) sells a blood dendritic cell isolation kit suitable for producing cirDC for research applications. The method involves magnetic depletion of T cell, monocytes and NK cells by retention on a depletion column, followed by positive selection of CD4+ blood dendritic cells using CD4 microbeads. The final positive selection step with CD4 antibody decreases IFN-α production and may cause apoptosis or anergy of the cells (Izaguire et al . , Abstract 106, presented at 6th International Workshop on Langerhans Cells, New York (1999)).
Cell separation procedures involving multiple density gradient centrifugation steps can be labor intensive, time consuming, poorly effective and poorly reproducible. Density gradient procedures also can lead to functional alterations of the DCs due to physical trauma during manipulation, or due to extended exposure to the gradient solutions themselves. Furthermore, density gradient procedures used to produce cirDC for therapeutic purposes can be difficult to automate, and also difficult to perform in a closed fluid path system.
Preparation of cirDC in a closed fluid path system is optimal for clinical applications, in that the cells are not exposed to environmental contaminants, and the operator is not exposed to any infectious agents present in the cell composition.
Procedures for dendritic cell isolation that require positive selection steps are also disadvantageous, in that the antibody or binding agent used to select or sort the DCs may activate the cells, or otherwise alter the functional properties of the cells.
Additionally, incomplete removal of the binding agent may cause adverse immunological reactions upon administration of the cells to humans.
Furthermore, positive selection methods result in isolation of only those DC that express the particular cell surface marker used in the selection procedure. However, it is now understood that there exist at least two distinct populations of cirDC in the blood, which differ quantitatively and qualitatively in expression of cell surface markers. Therefore, cirDC obtained by current positive selection methods may not be fully representative of the cirDC population in vivo.
The procedures currently used to produce cirDC by negative selection require a cocktail of antibodies, usually including antibodies reactive with T cells, B cells, monocytes, NK cells, and often progenitor cells. An effective procedure to produce cirDC in sufficient yield, purity and quality for therapeutic purposes using fewer antibodies has not been described. A simpler procedure would be advantageous in conserving reagents, time and labor.
Thus, there exists a need for a rapid, simple and reproducible method for producing high quality dendritic cells from the blood for use in therapeutic applications. Preferably, the method would avoid density gradient purification and positive selection steps.
Ideally, the entire method could be performed in a fully automated, closed fluid path system. The present invention satisfies this need and provides related advantages as well .
SUMMARY OF THE INVENTION
In accordance with the present invention, provided is a method for producing human circulating dendritic cells (cirDC) for therapeutic use, by depleting a human blood leukocyte composition of B cells, T cells and monocytes. The method is advantageous in that it is amenable to practice in a closed fluid path system, and the cirDC so produced are of sufficient number and quality for use in a variety of therapeutic applications.
Also provided are compositions containing cirDC for therapeutic use. The compositions can advantageously be administered to a patient to induce or enhance beneficial immune responses or to suppress pathogenic immune responses .
DETAILED DESCRIPTION OF THE INVENTION
The invention provides a method for producing human circulating dendritic cells (cirDC) for therapeutic use, comprising depleting a blood leukocyte composition of B cells, T cells and monocytes. The method is advantageous in that it can be used to simply and rapidly produce large numbers of high quality cirDC that are
representative of the dendritic cells in the blood. The method is also advantageous in that density gradient centrifugation and positive selection steps can be avoided, which could alter the functional properties of the cirDC or cause adverse effects upon administration to humans. Furthermore, the method can be fully automated and performed in a closed fluid path system, such that the operator is not exposed to infectious agents present in cell composition, and the cells are not exposed to environmental contaminants.
As used herein, the term "circulating dendritic cell" or "cirDC" refers to a leukocyte obtained from the blood that is characterized phenotypically as CD14- and HLA-DR+. A cirDC can be further characterized as lineage negative (lin-) , which indicates that the cirDC does not express surface antigens considered in the art to be characteristic of T cells, B cells, monocytes, NK cells, and hematopoietic progenitor cells. Thus, a cirDC which is lin- can be characterized, for example, as CD3-, CD19-, CD14-, CD16- and CD34-. The surface antigen designations used throughout this disclosure are consistent with the terminology set forth in the Protein Reviews on the Web (PROW) database available on the World Wide Web.
Throughout this disclosure, when referring to cell surface markers (e.g., CD14 antigen and the like), the term n+" is intended to indicate that as assessed by standard phenotyping procedures used in the immunological arts, such as FACS analysis, immunofluorescence or immunohistochemistry, the cells express the recited marker at levels similar to positive control cells . The term "-" indicates that under the same conditions, the cells express the recited marker at levels similar to
negative control cells. Exemplary methods to determine whether cells are "+" or "-" for CD3 , CD20, CD14, CDllc or HLA-DR are shown in Example 1, below. Antibodies to blood cell surface markers recited herein, which are suitable for phenotyping, are commercially available.
It is now thought that there are two phenotypically and functionally distinct dendritic cell populations in the blood, characterized by the differential expression of the β2 integrin CDllc. These two subsets may reflect different stages of maturation of dendritic cells in the blood, or may alternatively reflect different cell lineages.
CDllc+ cirDC and CDllc- cirDC have been reported to exhibit certain functional, phenotypic and morphological differences. For example, CDllc+ cirDC can be more potent stimulators of allogeneic T cell proliferation than CDllc- cirDC, and can endocytose particulate or soluble antigens more efficiently than CDllc- cells (see, for example, Robinson et al . , Eur . J. Immunol . 29:2769-2778 (1999); Kohrgruber et al . , J.
Immunol . 163:3250-3259 (1999); Pulendran et al . , Blood 94:213a (1999)). Furthermore, CDllc+ DCs can preferentially elicit Thl cytokines, whereas CDllc- DCs can preferentially elicit Th2 cytokines (Pulendran et al., supra (1999)).
Phenotypically, CDllc+ cirDC can be characterized by the expression of certain myeloid markers, such as CD13, CD33, CD32, CLA, or CDllb, which are not expressed, or only expressed at low levels, by CDllc- cirDC. Furthermore, HLA-DR, CD40, CD80 or CD86 can be expressed at higher levels by CDllc+ cirDC than by CDllc- cirDC. Both CDllc+ and Cdllc- cirDC can express
CD123 (the interleukin 3 receptor) and CD62L (the ligand for L-selectin) and CD4, although CDllc- can express these molecules at higher levels. The CDllc- cirDC population can also express CD45RA at much higher levels than the CDllc+ cirDC population (see, for example,
Robinson et al . , supra (1999); Pulendran et al . , supra (1999) )
Morphologically, CDllc+ cirDC can be characterized by exhibiting an irregular outline and hyperlobulated nucleus by light microscopy, and prominent cytoplasmic processes and lack of prominent ER by electron microscopy. In contrast, CDllc- cirDC possess a rounded morphology, with an oval or indented nucleus and a perinuclear pale zone by light microscopy, and fewer cytoplasmic processes and prominent ER by electron microscopy (see, for example, Robinson et al . , supra (1999) . Additional morphological features of these two cell types are described in Kohrgruber et al . , supra (1999) .
The methods of the invention produce human circulating dendritic cells for therapeutic use. As used herein, the phrase "for therapeutic use" refers to cirDC that are in a form and in an amount suitable for administration to humans. Thus, cirDC for therapeutic use are free from contact with substances that could potentially cause adverse immunological reactions in humans administered the cirDC. cirDC for therapeutic use also have not been exposed ex vivo to substances or manipulations that could potentially decrease their efficacy for a desired therapeutic purpose.
In one embodiment, cirDC for therapeutic use are free from contact with binding agents, such as
antibodies, that can be present on cirDC obtained by enrichment methods known in the art that involve positive^ selection or sorting steps. CirDC produced by positive selection methods are generally contacted with binding agents, and either captured on a solid support such as a bead or column and then released from the solid support, or segregated from unwanted cells by a procedure such as fluorescence activated cell sorting (FACS) . The binding agent itself, or the method of removing the binding agent from the cell, can alter the function or decrease the viability of the cirDC. If the binding agent is not effectively removed, the residual agent can potentially cause an adverse immunological reaction upon administration to a human. CirDC for therapeutic use that are free from contact with binding agents do not suffer from these disadvantages.
In another embodiment, cirDC for therapeutic use are free from contact with culture reagents, such as serum, non-human animal proteins, growth factors or other additives that can be present on dendritic cells that have been cultured ex vivo, even after washing the cells.
CirDC that are free from contact with culture reagents are advantageous in that they have not been exposed to infectious agents, such as prions or viruses, that are potentially present in serum, especially human serum pooled from multiple donors. Additionally, such cirDC are advantageous in that they have not been contacted with animal proteins or other substances that can stimulate the cirDC or cause adverse immunological reactions upon administration to humans. Furthermore, cirDC that are free from contact with culture reagents can be different from cultured cirDC in that they have not proliferated or differentiated ex vivo, which can
potentially alter their functional properties compared with the properties of cirDC as they exist in blood.
In a further embodiment, cirDC for therapeutic use are produced in a closed fluid path system. In such a system, the cirDC are not exposed to potential environmental contaminants, such as viruses or microorganisms, or to potential adverse environmental conditions, such as changes in ambient gases, that occur in methods that involve frequent opening of cell containers. As used herein, the term "closed fluid path system" refers to an assembly of components which are closed to the environment. Preferably, a closed fluid path system will include several cell containers, each of each of which is provided with one or more sterile connect-ports for effecting asceptic transfer of cells between the containers, and into and out of the containers, via sterile connect tubing.
An exemplary closed fluid path system for producing cirDC for therapeutic use is the ISOLEX 300i Magnetic Cell Selection System (Nexell Therapeutics Inc., Irvine, CA) , which can be used to deplete blood leukocytes of B cells, T cells and monocytes, as described further below.
Preferably, all steps from obtaining blood from an individual, to infusing the therapeutic composition into the individual, are carried out in a closed fluid path system. For example, peripheral blood from an individual can be collected and separated using an automated blood cell separator such as the CS3000 cell separator (Fenwal Division, Baxter Healthcare, Deerfield, 111.), which can be asceptically connected to an ISOLEX 300i. If desired, samples of cells at any stage can be
aseptically drawn off from the container system through sterile-connect ports for analysis. In methods involving antigen pulsing of the cirDCs, antigens can be asceptically added to the closed fluid path system through sterile-connect ports. In methods involving co-culturing of antigen pulsed cirDC with T cells, a closed culture container, such as the PL2417 culture bag (Baxter Immunothe apy, Round Lake, IL) described in PCT US95/13943, can be asceptically connected to the closed fluid path system. Finally, concentration of the cirDC or antigen-specific T cells into an infusible medium such as PLASMA-LYTE A (Baxter IV Systems, Round Lake, IL) can be carried out in the closed fluid path system, and the concentrated cells can be infused directly via the patient's intravenous line without exposing the cells to the environment .
The methods of the invention involve first obtaining a blood leukocyte composition from a human. As used herein, the term "blood leukocyte composition" refers to a composition containing cells obtained from blood, such as from peripheral blood or umbilical cord blood, that is substantially enriched for leukocytes (white blood cells) as compared with whole blood. The cellular composition of normal adult human blood is about 0.1% leukocytes, about 5% platelets, and about 95% red blood cells. Preferably, a blood leukocyte composition is substantially free of red blood cells. More preferably, a blood leukocyte composition is also substantially free of platelets. Thus, in one embodiment, a blood leukocyte composition used in the methods of the invention is a cellular composition of which at least about 70% of the cells, such as at least about 80%, 85%, 90%, 95%, 98% or more, are leukocytes.
Blood leukocytes are composed of mononuclear cells (including lymphocytes, monocytes, stem and progenitor cells, and cirDC) and granulocytes (including neutrophils, eosinophils and basophils) . Granulocytes normally comprise about 60-70% of blood leukocytes. Preferably, a starting blood leukocyte composition is substantially free of granulocytes cells. Thus, in one embodiment, a blood leukocyte composition used in the methods of the invention is a cellular composition of which at least about 70% of the cells, such as at least about 80%, 85%, 90%, 95%, 98% or more, are mononuclear cells .
Preferably, to obtain large numbers of blood leukocytes substantially free of granulocytes, the blood leukocyte composition will be a leukapheresis product. Leukapheresis avoids the potential damage and contamination of cells by density gradient procedures such as Ficoll separation. In a typical leukapheresis procedure, using commercially available blood cell separators and manufacturer's recommended settings for mononuclear cell collection, at least 1 x 109, such as at least 5 x 109, or 1 x 1010 mononuclear cells (MNCs) can be obtained from an individual over the course of several hours. Cell separators suitable for leukapheresis procedures are well known in the art, and include, for example, the Fenwal CS 3000 cell separator (Baxter International Inc, Deerfield, 111.), the Haemonetics MCS system (Haemonetics Corp., Braintree, Mass.), or the COBE Spectra Apheresis System (Gambro BCT) .
Blood from which a blood leukocyte composition is prepared can be obtained from the intended recipient of the ultimate therapeutic composition. Alternatively, blood can be obtained from an HLA-matched donor. For
certain therapeutic uses, blood can be obtained from an allogeneic donor. The term "HLA-matched" refers to an individual who expresses some or all of the seven different major histocompatibility complex (MHC) proteins on the cell surface in common with the intended recipient. In contrast, the term "allogeneic" indicates that the donor expresses none or few MHC proteins in common with the intended recipient . Whether or not two individuals are HLA-matched can be determined by standard tissue typing techniques using antibodies or by mixed lymphocyte reactions (MLR) .
Procedures that increase the total number of leukocytes in the blood, or that selectively increase the number of cirDC among blood leukocytes, can advantageously be used to increase the number of cirDC for therapeutic use obtained by the methods of the invention. Methods of increasing the number of leukocytes in the blood include, for example, administration of agents that induce the proliferation, differentiation and/or mobilization from the bone marrow of hematopoietic stem or progenitor cells. Agents that increase the number of leukocytes in the blood, by any of these mechanisms, are termed herein "mobilizing agents." Mobilizing agents include chemotherapeutic agents, irradiation and cytokines, or any combination of these agents. Mobilizing agents can increase the number of leukocytes in the blood by at least 2-fold, such as at least 5-fold, including at least 10-fold as compared with normal blood.
Agents that further increase the number of cirDC represented among blood leukocytes are termed herein "cirDC mobilizing agents." CirDC mobilizing agents can increase the number of cirDC among blood
leukocytes by at least 2-fold, such as at least 5-fold, 10-fold, 20-fold, 30-fold or more as compared with normal blood leukocytes.
Mobilizing agents useful in increasing the number of leukocytes in the blood include the following, alone or in any combination: ligand for the Flt3 receptor (FLT3L) , granulocyte colony stimulating factor (G-CSF) , granulocyte macrophage colony stimulating factor (GM-CSF) , stem-cell factor (SCF) , macrophage colony stimulating factor (M-CSF) , interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15) , leukemia inhibitory factor (LIF) , fibroblast growth factor (FGF) , platelet-derived growth factor (PDGF) , epidermal growth factor (EGF) , transforming growth factor beta (TGFβ) , tumor necrosis factor (TNF) interferons (IFN-α, IFNβ and IFN-γ) , and agonists of the receptors for any of these molecules, such as daniplestim, progenipoietin (ProGP) and myelopoietin (MPO) .
Preferred mobilizing agents for use in the methods of the invention are cirDC mobilizing agents. CirDC mobilizing agents include, for example, FLT3L, G-CSF, GM-CSF, and agonists of the receptors for these cytokines, such as progenipoietin (ProGP) which is a dual receptor agonist of both the G-CSF and the flt3 receptors (Fleming et al . , Blood 94:49a (1999)). A particularly preferred mobilizing agent is FLT3L, which is the subject of U.S. Patent Nos . 5,554,512 and 5,843,423. In preclinical studies, administration of FLT3L was shown to be safe and well tolerated at doses up to 100 μg/kg/day for 14 days, and to increase cirDC levels by up to 30-fold (Lebsack et al . , Blood 90:170a (1997)).
Administration of lOμg/kg/day of FLT3L for 10 consecutive days has been shown to increase cirDC in the blood that are phenotypically CDllc+IL3R- by 48-fold, and cirDC that are phenotypically CD11C-IL3R+ by 13-fold (see Pulendran et al . , supra (1999)). Another preferred mobilizing agent is G-CSF. Administration of lOμg/kg/day of G-CSF for 5 consecutive days has been shown to increase cirDC that are phenotypically CDllc-IL3R+ by 7-fold (see Pulendran et al . , supra (1999)) .
Mobilizing agents described herein can be obtained in recombinant form from commercial sources and are of sufficient purity for human administration. Alternatively, mobilizing agents can be prepared recombinantly by methods known in the art, given that their nucleic acid sequences are available in public databases and, further, plasmids containing the full-length sequences are commercially available. Mobilizing agents that act as agonists of cytokine receptors can be obtained commercially, designed rationally based on the known receptor structure, or obtained by screening compound libraries.
Appropriate dosages, schedules and routes for administration of mobilizing agents and cirDC mobilizing agents to individuals can be determined by a clinician, and will depend on factors such as the bioactivity of the particular agent, and the health and body weight of the individual .
CirDC comprise about 1% of mononuclear cells in blood of a normal individual not treated with a mobilizing agent. Accordingly, from 1 x 109 MNC obtained in a typically leukapheresis procedure, about 1 x 107 are cirDC. The methods of the invention can result in the
recovery of at least 10%, such as at least 20%, 40%, 60%, 80%, 90% or more of the cirDC present in a leukapheresis product obtained from an untreated individual . Accordingly, the methods of the invention in an untreated individual can be used to produce at least 1 x 10s cirDC, such as at least 1 x 106, 2 x 106, 4 x 106, 6 x 106, 8 x 10s, 9 x 10s or more cirDC.
An apheresis product obtained from an individual administered a mobilizing agent can contain at least 1 x 1010 MNC, such as at least 5 x 1010 MNC.
Accordingly, starting from an apheresis product obtained from an individual administered a mobilizing agent, given that about 1% of the MNCs are cirDC, and given a recovery of at least 10% of the cirDC, the methods of the invention can be used to obtain at least 1 x 107 cirDC for therapeutic use, such as at least 5 x 107 cirDC, 1 x 108 cirDC, or 5 x 108 cirDC.
The MNC in an apheresis product obtained from an individual administered a cirDC mobilizing agent can contain at least 2%, such as at least 5%, 10%, 20%, 30% or more cirDC. Starting from 5 x 1010 MNC, of which 5% are cirDC, with a recovery of 40% of the cirDC, it is apparent that at least 1 x 109 cirDC can readily be obtained by the methods of the invention. Depending on the starting number of MNC in the apheresis product, the percentage that are cirDC, and the efficiency of recovery of the cirDC, at least 2 x 109, such as 5 x 109, preferably 1 x 1010 cirDC for therapeutic use can be obtained by the methods disclosed herein.
The methods of the invention are practiced by depleting a blood leukocyte composition of B cells, T cells and monocytes . As used herein, the term
"depleting" refers to any procedure that substantially removes the indicated cell type from the blood leukocyte composition without also substantially removing cirDC from the composition.
The term "substantially removes" with respect to depletion of each of the cell types is intended to mean removal of at least 50% or more of the particular cell type, such as at least 75%, 80%, 90%, 95%, or 97%, including at least 99%, 99.5%, 99.9% or more of the particular cell type. Thus, by depleting B cells, T cells and monocytes from a blood leukocyte composition, the remaining cells are substantially enriched for cirDC. As used herein, the term "substantially enriched" is intended to mean that the cell composition obtained by the method contains at least 50%, preferably at least
70%, more preferably at least 80%, 95%, 97%, 99% or more cirDC for therapeutic use .
The functional, morphological and phenotypic characteristics of B cells (also called B lymphocytes) , T cells (also called T lymphocytes) , monocytes and other hematopoietic cells are well known in the art and are reviewed in standard immunology textbooks, such as Kuby, Immunology 3rd ed. , W.H. Freeman, New York (1997). As used herein, the term "T cell" refers to a leukocyte that is CD3+, the term "B cell" refers to a leukocyte that is CD20+, and the term "monocyte" refers to a leukocyte that is CD14+. These cells will also possess the functional and morphological characteristics of the particular cell type .
A preferred method of depleting a particular cell type involves binding the desired cell with a cell selective binding agent so as to form a complex, and
removing the bound complex from the composition. However, other methods of depleting B cells, T cells or monocytes are known in the art or can be readily determined. Such methods, include, for example, erythrocyte rosetting (preferably using human erythrocytes) , which can be used to deplete T cells; cell size or density separations (eg. counterflow elutriation) , which can be used to deplete T cells, B cells or monocytes; complement-mediated cell lysis (eg. using CAMPATH antibody) , which can be used to deplete T cells or B cells; adherence to plastic, which can be used to deplete monocytes; and combinations of these methods.
In the methods described herein, B cells, T cells and monocytes, and optionally granulocytes, can be depleted individually in any order, or in any combination. Thus, B cells, T cells and monocytes, and optionally granulocytes, can be depleted sequentially or simultaneously.
As used herein, the term "cell selective binding agent" is a molecule that binds with high affinity to a molecule present on the surface of a recited hematopoietic cell, that is not also substantially present on the surface of a cirDC. Cell selective binding agents bind to molecules present at levels on the indicate cell type that are at least 10-fold, such as at least 100-fold, including at least 1000-fold higher than on cirDC. Methods of determining whether a surface molecule is expressed by a given cell, which will guide the choice of binding agent, are well known in the art and include, for example, immunofluorescence, FACS, radioimmunoassay, immunoprecipitation, mRNA expression analysis, and the like.
A cell selective binding agent need not bind exclusively to the indicated cell type so long as it does not also bind cirDC to a substantial extent. Thus, a cell selective binding agent can bind molecules found on both B cells and T cells, or on all three cell types. A cell selective binding agent can also bind molecules found on other blood cells.
Preferred cell selective binding agents do not activate blood leukocytes. Binding agents that activate leukocytes can induce the production of cytokines that can alter the functional properties of cirDC. Furthermore, residual activated leukocytes obtained together with cirDC can cause adverse effects upon administration to an individual (see, for example, Hsu et al . , Transp1antation 68:545-554 (1999); and Richards et al., Cancer Res. 59:2096-2101 (1999)).
An exemplary list of molecules present on the surface of B cells is: CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD40, CDw75, CD76, the Ig light chains and λ, and the Ig heavy chains γ, a, μ, δ., and e. Thus, a B cell selective binding agent can be a binding agent that binds any of these molecules, such as an antibody specific for any of these molecules. Preferred B cell selective binding agents bind to CD19, CD20, CD21, CD22 or CD37. Particularly preferred B cell selective binding agents bind to CD19 or CD20.
An exemplary list of molecules present on the surface of T cells is: CD2, CD3 , CD4, CD5, CD6, CD7, CD8, CD27, CD28, CD32, CD43, and the T cell receptor α, β, y or δ chains. Thus, a T cell selective binding agent can be a binding agent that binds any of these molecules, such as an antibody specific for any of these molecules.
Preferred T cell selective binding agents bind to CD2 , CD3, CD4, CD5, CD7 , CD8 , or the TCR or β chains. Particularly preferred T cell selective binding agents bind to CD2 or CD3.
An exemplary list of molecules present on the surface of monocytes is: CDwl2, CD13, CD14, CD15, CDwl7, CD31, CD32, CD33, CD64 , CD98. Thus, a monocyte selective binding agent can be a binding agent that binds any of these molecules, such as an antibody specific for any of these molecules. A preferred monocyte selective binding agent binds to CD14.
The blood leukocyte composition can optionally be further depleted of granulocytes using at least one granulocyte selective binding agent. An exemplary list of molecules present on the surface of granulocytes is CD66b, CD15, CD24, and the like. Thus, a granulocyte selective binding agent can be a binding agent that binds any of these molecules, such as an antibody specific for CD66b, CD15, or CD24. Depleting the blood leukocyte composition of granulocytes using a granulocyte selective binding agent is particularly advantageous when the starting blood leukocyte composition contains a significant number of mature or immature granulocytes. For example, when blood is obtained from an individual administered a mobilizing agent such as G-CSF, GM-CSF, or progenipoietin (ProGP) , a blood leukocyte composition can contain a large number of mature and immature granulocytes. Immature granulocytes can be difficult to separate from mononuclear cells using cell separators, but can advantageously be depleted using a granulocyte selective binding agent. Those skilled in the art can readily determine the desireability of depleting the
blood leukocyte composition of granulocytes using a granulocyte selective binding agent.
A binding agent useful in the methods of the invention will form a high affinity binding complex with the target cell. As used herein, the term "complex" refers to an interaction between the binding agent and the target cell that has a dissociation constant (Kd) of less than about 10"5 M, such as less than about 10"7 M, including less than about 10"9 M. A preferred binding agent is an antibody, such as a monoclonal, recombinant or single chain antibody, or an antigen binding fragment therefrom, which forms a high affinity complexes with target molecules. Antibodies suitable for use in the methods of the invention are commercially available, or can be produced with high affinity for a desired surface molecule by methods known in the art. Such antibodies can be derived from a single species, including human, rodent, sheep and goat, or can be chimeric.
Preferred cell selective binding agents bind to all or to the majority of the indicated cell type.
However, combinations of cell selective binding agents can be used to more completely deplete a particular cell type. As an example, CD4 is expressed on about 65% of T cells, with the remainder expressing CD8. Thus, a combination of binding agents that bind CD4 and CD8 can be used to deplete T cells.
Cell selective binding agents other than antibodies can also be used in the methods of the invention. Such binding agents include lectins, such as soybean agglutinin, which binds to T cells and B cells. Commercially available libraries of small molecule or macromolecular compounds can also be screened using whole
B cells, T cells or monocytes, or membranes or isolated surface molecules therefrom, to identify other binding agents . Methods of screening and selecting for binding compounds, including automated screening and selection methods, are well known in the art. The particular method employed will depend on the nature of the compounds being screened. Thus, a cell selective binding agent can be essentially any chemical or biological compound with the appropriate selectivity and affinity for the desired cell, such as a nucleic acid, peptide, peptidomimetic, small organic molecule, or the like.
In one embodiment, target cells are contacted with a binding agent under conditions where complexes are formed between the binding agent and the target cell . Such conditions can be determined by the practitioner, and will depend on factors such as the nature and affinity of the binding agent, the volume of the blood leukocyte composition, and the number of target cells and contaminating cells in the composition. As an example, conditions suitable to form a complex between a binding agent and a target cell are conditions equivalent to contacting 1 x 107 mononuclear cells in a 1 ml volume with 1.5 μg monoclonal antibody for 30 mins . at room temperature .
In one embodiment, an invention depleting method consists of contacting blood leukocytes with binding agents selective for T cells, B cells and monocytes, with no other depleting steps. In an alternative embodiment, an invention depleting method comprises or consists of contacting blood leukocytes with binding agents selective for two cell types selected from the group consisting of T cells, B cells and monocytes.
For example, blood leukocytes optionally are not also contacted with a natural killer (NK) cell selective binding agent, such as an antibody specific for CD16, CD56, or for other molecules present in abundance on NK cells that are not present at significant levels on cirDC. As a further example, blood leukocytes optionally are not also contacted with a stem cell selective binding agent, such as an antibody specific for CD34, or for other molecules present in abundance on stem cells that are not present at significant levels on cirDC.
Practicing the methods of the invention with the minimum number of reagents and steps possible is advantageous in saving time, money and handling of the cells.
In an alternative embodiment, an invention depleting method consists of contacting blood leukocytes with one or more binding agents selective for T cells, B cells, monocytes and granulocytes, with no other depleting steps. In another alternative embodiment, depleting consists of contacting blood leukocytes with binding agents selective for two cell types selected from the group consisting of T cells, B cells and monocytes, and additionally contacting blood leukocytes with a binding agent selective for granulocytes, with no other depleting steps. Thus, a method for producing human circulating dendritic cells for therapeutic use can comprise, or consist of, contacting blood leukocytes with binding agents selective for T cells, monocytes and granulocytes. As described previously, the use of granulocyte selective binding agents to deplete granulocytes is particularly advantageous when the starting blood leukocyte composition contains a significant number of mature or immature granulocytes, such as when the blood has been obtained from an
individual administered a mobilizing agent that increases granulocyte number.
Following contacting the target cell with the cell selective binding agent, the complex of the binding agent and cell is removed, thus depleting the target cell from the composition. A variety of methods are known in the art to remove binding agent-cell complexes from compositions .
For example, the binding agent can be labeled with a detectable moiety, such as a fluorochrome, and the complexes separated by flow cytometry using a sorter that separates cells having the detectable moiety from those that do not, such as a fluroescence activated cell sorter. (FACS) . Alternatively, removal of the complex can involve linking the binding agent, either directly or through a secondary binding agent, to a solid support that allows the complex to be separated from unbound cells in the suspension by virtue of binding affinity, density, magnetism or other physical property.
As used herein, the term "secondary binding agent" refers to any molecule or combination of molecules that provides a means of linking the binding agent to the solid support. Exemplary secondary binding agents include antibodies, which can be prepared by known methods so as to have affinity for virtually any cell selective binding agent and can be linked directly to solid supports; biotin and avidin, one of which can be linked to a binding agent and the other of which can be linked to a solid support; Protein A or Protein G, which have affinity for antibodies and can be linked to solid supports, and the like.
Exemplary solid supports include paramagnetic beads, which allow the complexes to be removed with a magnet; chromatography columns and hollow fibers, which allow the complexes to be removed by virtue of size, density or affinity to the matrix; and polystyrene surfaces, which allow the complexes to be removed by panning methods. A variety of secondary binding agents and compatible solid supports are commercially available or can be readily prepared for a particular application.
In one embodiment, the solid support is directly attached to the binding agent. For example, a cell selective binding agent can be conjugated to a paramagnetic bead, and the complex removed from the composition with a magnet. In another embodiment, the solid support is attached to a secondary binding agent. For example, a target cell-binding agent complex can be further contacted with a secondary binding agent (eg. an antibody) conjugated to a paramagnetic bead, and the cell-binding agent-secondary binding agent complex removed from the composition with a magnet.
Paramagnetic beads, antibody-bound paramagnetic beads, magnets and automated systems for magnetic cell separation are commercially available, and detailed protocols for their use are available from the suppliers.
In a preferred embodiment, all depletion steps are conducted in a magnetic cell separation apparatus as described, for example, in U.S. Patent No. 5,536,475. An exemplary apparatus is the ISOLEX 300i fully automated magnetic cell separation system (Nexell Therapeutics, Inc., Irvine CA) . Suitable binding agents for use in such an apparatus include cell-specific GMP antibodies, which are commercially available. Depletion in a
magnetic cell separation apparatus can be performed, for example, using sheep anti-mouse polyclonal antibodies and paramagnetic beads produced by Dynal A/S (Oslo, Norway) .
The methods described above produce a cirDC population for therapeutic use that contains both CDllc÷ and CDllc- cirDC. If desired for a particular application, either CDllc+ cirDC or CDllc- cirDC can be further enriched using binding agents selective for the cell surface markers preferentially expressed by the unwanted cell population, and similar depletion methods as described.
In one embodiment, the cirDC are further depleted of CDllc+ cirDC to produce CDllc- cirDC for therapeutic use. As an example, CDllc+ cirDC can be depleted by contacting cirDC with CDllc specific antibodies to form a complex, contacting the complex with secondary antibodies linked to paramagnetic beads, and removing the complexes with magnets. In an alternative embodiment, cirDC are further depleted of CDllc- cirDC to produce CDllc+ cirDC for therapeutic use. As an example,
CDllc- cirDC can be depleted by contacting cirDC with CD45RA specific antibodies to form a complex, contacting the complex with secondary antibodies linked to paramagnetic beads, and removing the complexes with magnets.
Optionally, the cirDC produced by the methods of the invention are washed with sterile buffers, concentrated and suspended in an infusible medium before use . The cirDC can be infused into the recipient by a variety of routes, such as into the blood, into a lymph node, or by intradermal or subcutaneous administration
(see, for example, Morse et al . , Cancer Res . 59:56-58 (1999) ) .
The cirDC can be used in a variety of therapeutic applications, including in therapeutic applications where dendritic cells produced by other methods are useful. For example, the cirDC can first be pulsed with a desired antigen ex vivo, using methods known in the art for pulsing dendritic cells, and used to induce or enhance an immune response against the antigen so as to prevent or ameliorate a pathological condition (see, for example, Morse et al . , Clin. Cancer Res. 5:1331-1338 (1999); Nestle et al . , Nature Med. 4:328-332 (1998) ) . In an exemplary method of preparing antigen-pulsed cir DC, the cirDC, at a concentration of several million/ml, can be co-incubated with antigen, at a concentration of about 10-200 μg/ml, for a period of from several hours to several days .
Exemplary antigens for pulsing of cirDC include products of oncogenes, viral proteins, cell lysates, and normal cellular components that are either modified or aberrantly expressed in a pathology. Contemplated antigens for use in cancer therapy include, for example, whole antigens, peptides or mRNA derived from carcinoembryonic antigen (CEA) (e.g. for breast or colon cancer); Her2/neu (e.g. for breast or ovarian cancer); prostate specific antigen (PSA) and prostate specific membrane antigen (PMSA) (e.g. for prostate cancer); MUC (e.g. for breast cancer) ; MAGE, GP100, tyrosinase or MARTI (e.g. for melanoma) ; and tumor cell lysates (e.g. for renal or liver cancer) or apoptotic tumor cells.
Contemplated antigens for use in the prevention or treatment of infectious conditions include human
immunodeficiency virus (e.g. HIV-1 and HIV-2) , hepatitis B virus, hepatitis C virus, papilloma virus, cytomegalovirus, Epstein-Barr virus, and chlamydia, as well as antigenic preparations therefrom.
The antigen-pulsed cirDC produced by the methods of the invention will acquire the exogenous antigen, process it into peptides and, upon infusion into the patient, present the peptides to T cells in the context of MHC molecules to induce an immune response against the tumor or infected cell. For such an application at least about 10s, preferably at least about 107, more preferably at least about 108 antigen-pulsed cirDC can be used.
Alternatively, the antigen-pulsed cirDC can be co-cultured for a suitable period of time, such as from several hours to several days, with T lymphocytes, to produce antigen-specific T cells. Such T cells are activated by contact with the antigen-pulsed T cells, and will induce an immune response against cells expressing the target antigen on their surface when infused into an individual. The T cells can be obtained, by methods known in the art , from the same donor whose blood leukocytes yielded the DC, or from an HLA-matched individual as described above. A T cell population for antigen-pulsing can contain both cytotoxic T cells (CD8+ T cells) and helper T cells (CD4+ T cells) or, using preselection methods known in the art, can contain primarily cytotoxic T cells.
When cirDC are intended to be used as stimulators of T cells ex vivo, the number of antigen-pulsed cirDC required can be in the range of about 0.5 million to about 100 million. This range is
based on the assumption that a ratio of 1:5 to 1:10 DC:T-cells is required for efficient activation of the T-cells. It is estimated that about 10 million to 1 billion antigen-specific T-cells are required to achieve the desired cell-killing activity in vivo, and that activated T-cells will comprise about 10% of the total T-cells in a co-culture. Therefore, about 100 million to 10 billion T-cells are needed in the final co-culture. Assuming a proliferation index (PI) of 10 for the T-cells in culture (although a PI of from 10-50 is expected) , about 5 million to about 1 billion T-cells are seeded in the beginning co-culture. Thus, at a ratio of 1:10, DC: T-cells, from about 0.5 million to about 100 million antigen-pulsed DC are needed in the co-culture.
The cirDC of the invention can also be used therapeutically without antigen-pulsing. For example, cirDC can be administered in applications where enhancement of the immune system is desired, such as to reconstitute the immune system after bone marrow transplantation. Additionally, cirDC can be administered together with, prior to, or following treatment of a tumor with an agent that induces tumor apoptosis (e.g. a chemotherapeutic agent or irradiation) . In such an application, the administered cirDC can take up and present tumor antigens from the apoptosed tumor cells so as to activate the immune system to kill residual tumor cells and/or prevent tumor metastases.
Furthermore, cirDC can be used in a variety of immunosuppressive applications, including in the therapy of autoimmune diseases and in promoting tolerance to transplanted tissues (see, for example, Thomson et al . , Transplantation 68:1-8 (1999); U.S. Patent No. 5,871,728) . For example, cirDC obtained from an
allogeneic tissue donor can be administered to the tissue recipient so as to reduce the likelihood of rejection of the allograft . For tolerogenic applications, it can be advantageous to first treat the cirDC with an agent, such as TGFβ, IL-10 or cyclosporine A, that decreases expression by the cirDC of co-stimulatory molecules and immunostimulatory cytokines.
It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also included within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.
EXAMPLE I Small-scale preparation of cirDC
This example shows the preparation of cirDC by depleting blood leukocytes of T cells, B cells and monocytes .
Platelet-washed peripheral blood mononuclear cells (PBMCs) (1 x 107 cells in 1 ml) were resuspended in phosphate buffered saline (PBS; Biowhittaker) containing 1% human serum albumin (HSA) and 12% sodium citrate. Cells were contacted sequentially with mouse CD2 antibody (Nexell Therapeutics) , mouse CD19 antibody (Nexell
Therapeutics) , or mouse CD14 antibody (Diaclone) for 30 min at room temperature (RT) . Each primary antibody was used at a concentration of 1.5 μg/107 cells/ml. After incubation with each primary antibody, the cells were washed with PBS containing 1% HSA and 12% sodium citrate to remove primary antibodies and incubated with sheep anti-mouse paramagnetic beads (SAM beads; Dynal) at a 2
bead:PBMC ratio for 30 min at RT. The bead/cell rosettes were washed and removed using an MPC7-1 Dynal Magnetic Particle Concentrator.
The unbound cells were collected, washed, resuspended and analyzed by FACS analysis for expression of surface markers, using the following labeled antibodies, obtained from Becton Dickinson, following the manufacturer's recommended procedures: anti-IgGl FITC/anti-IgGl PE (control) ; anti-CD2 FITC; anti-CD3 FITC; anti-CD14 FITC; anti-CD19-FITC; anti-CD20 FITC; anti-CDllc FITC/anti-DR PE/anti-CD14 PCP. FACS data was acquired using a FACScan™ flow cytometer (Becton Dickinson) . The percentage of cells that were CD3+ (ie. T cells), CD20+ (ie. B cells), CD14+ (ie. monocytes), CD16+56+ (i.e. NK cells), or
CD11C+/HLA-DR/CD14- (ie. a subpopulation of cirDC) following various depletion steps in a single experiment is shown in Table 1, and the absolute numbers of each cell type are shown in Table 2.
TABLE 1
TABLE 2
These results show that by contacting peripheral blood mononuclear cells from an untreated individual with binding agents selective for B cells, T cells and monocytes, and removing the complexes from the composition, a cell population enriched for CD11C+/HLA-DR+/CD14- cirDC by at least about 8-fold can be produced. These results further show that at least 45% of the CD11C+/HLA-DR+/CD14- cirDC in the starting population can be recovered by these methods.
The results obtained from the above experiment and four additional experiments, using either CD2 or CD3 antibodies to deplete T cells, are shown in Tables 3 and 4, below. The data presented in Table 4 shows an average recovery of about 52% of cirDC by depleting a human blood leukocyte composition of B cells, T cells and monocytes using CD2 , CD19 and CD14 antibodies, and an average recovery of about 58% of cirDC using CD3, CD19 and CD14 antibodies.
TABLE 3
TABLE 4
EXAMPLE II Large-scale preparation of cirDC
This example shows the preparation of cirDC for therapeutic use.
Apheresis samples from individuals administered lOμg/kg/ml FLT3L (Immunex) for 10 days are collected using a Fenwal CS-3000 Cell Separator. Peripheral blood mononuclear cells (PBMCs) (1 x 1010 cells) are resuspended in PBS containing 1% HSA and 12% sodium citrate. Cells are sensitized sequentially with 1 mg CD2 antibody (Nexell Therapeutics) , 1 mg CD19 antibody (Nexell Therapeutics) , or 1 mg CD14 antibody (Diaclone) for 30 min at room temperature (RT) , or with all three antibodies together, in an ISOLEX 300i cell selection device. Unbound antibodies are removed by washing and the antibody sensitized cells are incubated with sheep anti-mouse paramagnetic beads (Dynal) at a 2 bead:PBMC ratio for 30 min at RT. The bead/cell rosettes are washed and the unbound cells are collected, washed and resuspended.
From a FLT3L-mobilized donor, at least 10%, such as about 60% of the PBMCs are cirDC. Thus, given a recovery of at least 50% of the starting cirDC, at least 5 x 108 cirDC, such as about 3 x 109 cirDC for therapeutic use are obtained from a single apheresis product from a FLT3L-mobilized donor containing 1010 cells. These cirDC effectively process and present antigen, as assessed by pinocytosis assays, activity in allogeneic mixed lymphocyte assays, and antigen-induced T cell proliferation assays.
Throughout this application various patents and publications have been referenced. The disclosures of these patents and publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.
Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.
Claims (43)
1. A method for producing human circulating dendritic cells (cirDC) for therapeutic use, comprising depleting a human blood leukocyte composition of B cells, T cells and monocytes.
2. The method of claim 1, wherein said blood leukocyte composition is substantially free of granulobytes .
3. The method of claim 1, wherein said blood leukocyte composition is obtained from an individual administered at least one mobilizing agent.
4. The method of claim 3 , wherein said mobilizing agent is selected from the group consisting of FLT3L, G-CSF, GM-CSF, SCF, M-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, LIF, FGF, TNF, ProGP, FGF, PDGF, EGF, TGF, interferon, daniplestim, progenipoietin (ProGP) and myelopoietin (MPO) .
5. The method of claim 4 , wherein said mobilizing agent is a cirDC mobilizing agent.
6. The method of claim 5, wherein said cirDC mobilizing agent is FLT3L.
7. The method of claim 1, wherein said blood leukocyte composition comprises at least 1 x 109 mononuclear cells.
8. The method of claim 1, wherein said cirDC for therapeutic use are free from contact with binding agents .
9. The method of claim 1, wherein said cirDC for therapeutic use are free from contact with serum and non-human animal proteins .
10. The method of claim 1, wherein said depleting occurs in a closed fluid path system.
11. The method of claim 1, wherein said cirDC for therapeutic use comprise at least 1 x 10s cirDC.
12. The method of claim 3, wherein said blood leukocyte composition comprises at least 1 x 1010 mononuclear cells.
13. The method of claim 12, wherein said cirDC for therapeutic use comprise at least 1 x 107 cirDC.
14. The method of claim 5, wherein said cirDC for therapeutic use comprise at least 1 x 108 cirDC.
15. The method of claim 6, wherein said cirDC for therapeutic use comprise at least 1 x 109 cirDC.
16. The method of claim 1, wherein said depleting comprises:
(a) contacting: said B cells with at least one B cell selective binding agent; said T cells with at least one T cell selective binding agent; and said monocytes with at least one monocyte selective binding agent, under conditions where complexes are formed between said B cells and said B cell selective binding agent, said T cells and said T cell selective binding agent, and said monocytes and said monocyte selective binding agent ; and
(b) removing said complexes from said blood leukocyte composition.
17. The method of claim 16, further comprising contacting granulocytes with a granulocyte selective binding agent under conditions where complexes are formed between said granulocytes and said granulocyte selective binding agent, and removing said complexes from said blood leukocyte composition.
18. The method of claim 1, wherein said depleting consists of :
(a) contacting said B cells with at least one B cell selective binding agent, said T cells with at least one T cell selective binding agent, and said monocytes with at least one monocyte selective binding agent under conditions where complexes are formed between said B cells and said B cell selective binding agent, said T cells and said T cell selective binding agent, and said monocytes and said monocyte selective binding agent; and
(b) removing said complexes from said blood leukocyte composition.
19. The method of claim 16, wherein said B cell selective binding agent binds to a molecule selected from the group consisting of CD19, CD20, CD21, CD22, CD2 , CD24, CD37, CD40, CDw75, CD76 and an Ig chain.
20. The method of claim 19, wherein said B cell selective binding agent binds to CD19 or CD20.
21. The method of claim 16, wherein said T cell selective binding agent binds to a molecule selected from the group consisting of CD2 , CD3 , CD4, CD5, CD6, CD7, CD8, CD27, CD28, CD32, CD43, and a T cell receptor or β chain.
22. The method of claim 17, wherein said granulocyte selective binding agent binds to a molecule selected from the group consisting of CD66b, CD15 and CD24.
23. The method of claim 21, wherein said T cell selective binding agent binds to CD2 or CD3.
24. The method of claim 16, wherein said monocyte selective binding agent binds to a molecule selected from the group consisting of CDwl2 , CD13, CD14, CD15, CDwl7, CD31, CD32, CD33, CD64, CD98.
25. The method of claim 24, wherein said monocyte selective binding agent binds to CD14.
26. The method of claim 16, wherein
(a) said B cell selective binding agent binds to CD19 or CD20,
(b) said T cell selective binding agent binds to CD2 or CD3, and
(c) said monocyte selective binding agent binds to CD14.
27. The method of claim 16, wherein said B cell selective binding agent, said T cell selective binding agent or said monocyte selective binding agent is an antibody.
28. The method of claim 27, wherein said B cell selective binding agent, said T cell selective binding agent and said monocyte selective binding agent are antibodies.
29. The method of claim 1, wherein said blood leukocytes are not contacted with a binding agent selective for NK cells.
30. The method of claim 1, wherein said blood leukocytes are not subjected to density gradient centrifugation.
31. The method of claim 1, wherein said depleting of said B cells, T cells and monocytes is performed sequentially.
32. The method of claim 1, wherein depleting of said B cells, T cells and monocytes is performed simultaneously.
33. The method of claim 16, wherein said B cell selective binding agent, said T cell selective binding agent or said monocyte selective binding agent is attached to a solid support.
34. The method of claim 33, wherein said solid support is a paramagnetic bead.
35. The method of claim 16, further comprising contacting said B cell-binding agent complex, said T cell-binding agent complex or said monocyte-binding agent with a secondary binding agent attached to a solid support .
36. The method of claim 35, wherein said secondary binding agent is an antibody.
37. The method of claim 35, wherein said solid support is a paramagnetic bead.
38. The method of claim 1, further comprising depleting the cirDC of CDllc- cirDC.
39. The method of claim 1, further comprising depleting the cirDC of CDllc+ cirDC.
40. A method for producing human circulating dendritic cells (cirDC) for therapeutic use, comprising depleting a human blood leukocyte composition of T cells, monocytes and granulocytes .
41. The method of claim 40, wherein said depleting comprises:
(a) contacting: T cells with at least one T cell selective binding agent; monocytes with at least one monocyte selective binding agent; and granulocytes with at least one granulocyte selective binding agent, under conditions where complexes are formed between said T cells and said T cell selective binding agent, said monocytes and said monocyte selective binding agent, and said granulocytes with said granulocyte selective binding agent ; and
(b) removing said complexes from said blood leukocyte composition.
42. A cell composition comprising at least 1 x 106 cirDC for therapeutic use, produced by the method of claim 1.
43 . A cell composition comprising at least 1 x 109 cirDC for therapeutic use , produced by the method of claim 6 .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57853200A | 2000-05-24 | 2000-05-24 | |
US09578532 | 2000-05-24 | ||
PCT/US2001/016845 WO2001090316A2 (en) | 2000-05-24 | 2001-05-23 | Human circulating dendritic cell compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001274934A1 true AU2001274934A1 (en) | 2001-12-03 |
Family
ID=24313267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001274934A Abandoned AU2001274934A1 (en) | 2000-05-24 | 2001-05-23 | Human circulating dendritic cell compositions and methods |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030129166A1 (en) |
EP (1) | EP1287120A2 (en) |
JP (1) | JP2003534006A (en) |
AU (1) | AU2001274934A1 (en) |
MX (1) | MXPA02011592A (en) |
WO (1) | WO2001090316A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005506372A (en) * | 2001-10-24 | 2005-03-03 | ザ コーポレーション オブ ザ トラスティーズ オブ ザ オーダー オブ ザ シスターズ オブ メルシー イン クィーンズランド | Methods for modulating immune activity of immunoresponsive grafts by progenipoietin |
EP1824886B1 (en) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
EP1966369B1 (en) * | 2005-12-21 | 2010-10-06 | Sentoclone AB | Method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
CN106463711B (en) * | 2014-03-24 | 2021-05-07 | 康奈尔大学 | Dendrite inhibiting electrolyte for metal-based batteries |
CA2914595C (en) * | 2014-05-19 | 2022-12-13 | F. Hoffmann-La Roche Ag | Method for producing antibodies using ovine b-cells and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643786A (en) * | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
US6458585B1 (en) * | 1996-08-14 | 2002-10-01 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
EP0922758B1 (en) * | 1997-10-27 | 2009-04-15 | Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
AU1220599A (en) * | 1997-11-14 | 1999-06-07 | Hemosol Inc. | Method for the production and use of dendritic cells |
-
2001
- 2001-05-23 AU AU2001274934A patent/AU2001274934A1/en not_active Abandoned
- 2001-05-23 EP EP01941595A patent/EP1287120A2/en not_active Withdrawn
- 2001-05-23 MX MXPA02011592A patent/MXPA02011592A/en unknown
- 2001-05-23 JP JP2001587112A patent/JP2003534006A/en not_active Withdrawn
- 2001-05-23 WO PCT/US2001/016845 patent/WO2001090316A2/en not_active Application Discontinuation
-
2002
- 2002-09-09 US US10/238,986 patent/US20030129166A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001090316A2 (en) | 2001-11-29 |
JP2003534006A (en) | 2003-11-18 |
WO2001090316A3 (en) | 2002-05-10 |
EP1287120A2 (en) | 2003-03-05 |
US20030129166A1 (en) | 2003-07-10 |
MXPA02011592A (en) | 2004-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McKenna Jr et al. | Good manufacturing practices production of natural killer cells for immunotherapy: a six‐year single‐institution experience | |
US5866115A (en) | Process for preparing dendritic cells, cells thus produced and containers for carrying out this process | |
ES2523366T3 (en) | Use of a tangential flow filtration device and methods for leukocyte enrichment | |
CA1340565C (en) | Device and process for cell capture and recovery | |
AU2010202385A1 (en) | Methods for inducing the differentiation of blood monocytes into functional dendritic cells | |
Ebner et al. | Generation of large numbers of human dendritic cells from whole blood passaged through leukocyte removal filters: an alternative to standard buffy coats | |
US6143508A (en) | Device and process for cell capture and recovery | |
WO2003010292A2 (en) | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors | |
US20030129166A1 (en) | Human circulating dendritic cell compositions and methods | |
JP4435985B2 (en) | Method for producing TcRγδT cells | |
WO2004027052A1 (en) | Th1 cell adoptive immunotherapy | |
WO2002036748A2 (en) | Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells | |
Gluckman | Umbilical cord blood biology and transplantation | |
Beaujean | Methods of CD34+ cell separation: comparative analysis | |
EP1268746A2 (en) | PRODUCTION OF TcR GAMMA DELTA T CELLS | |
US20080241815A1 (en) | Methods for Inducing the Differentiation of Blood Monocytes into Functional Dendritic Cells | |
US8313945B2 (en) | Methods for inducing the differentiation of blood monocytes into functional dendritic cells | |
CN112424342A (en) | Compositions and methods for culturing and expanding cells | |
JP2023103632A (en) | Nk cell culturing method | |
Magee et al. | Isolation, culture and propagation of natural killer cells | |
Cameron et al. | Isolation of human tonsillar dendritic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |